Clinical Trial

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-06.
Status change: Not Yet Recruiting → Recruiting 2025-08-30
Trial Details
NCT Number NCT06868485
Lead Sponsor Wayshine Biopharm, Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 40 participants
Start Date 2025-08-18
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08